论文部分内容阅读
目的:探讨血清细胞角蛋白19片段(CYFRA21-1)和恶性肿瘤特异性生长因子(TSGF)联合检测对鼻咽癌(NPC)的临床诊断价值。方法:采用电化学发光免疫分析等技术,检测正常对照组50例、良性疾病组25例、NPC组82例血清中的CYFRA21-1及TSGF表达水平。结果:NPC组CYFRA21-1、TSGF敏感性分别为48.8%、57.3%,其测定值均明显高于正常对照组和良性疾病组(均P<0.01)。CYFRA21-1、TSGF两项联合检测可使敏感性提高到74.3%,且特异性没有明显下降。结论:CYFRA21-1、TSGF可作为NPC临床诊断的血清肿瘤标志物,两项联合检测结果更理想。
Objective: To investigate the clinical value of combined detection of serum cytokeratin 19 (CYFRA21-1) and malignant tumor specific growth factor (TSGF) in the diagnosis of nasopharyngeal carcinoma (NPC). Methods: The expression of CYFRA21-1 and TSGF in serum of 50 cases of normal control group, 25 cases of benign disease group and 82 cases of NPC group were detected by electrochemiluminescence immunoassay. Results: The sensitivity of CYFRA21-1 and TSGF in NPC group were 48.8% and 57.3% respectively, which were significantly higher than those in normal control group and benign disease group (all P <0.01). CYFRA21-1, TSGF two joint detection can increase the sensitivity to 74.3%, and no significant decrease in specificity. Conclusion: CYFRA21-1 and TSGF can be used as serum tumor markers in the clinical diagnosis of NPC. The results of the two combined tests are more satisfactory.